Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect
- PMID: 22977595
- PMCID: PMC3440819
- DOI: 10.3892/etm.2011.315
Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect
Abstract
The aim of this study was to investigate the relationship between tissue concentrations and exposure times or therapeutic effect of an anthracycline anticancer drug, pirarubicin, in bladder cancer tissue after single intravesical administration against superficial bladder cancer. The concentrations of pirarubicin in tumor tissues and serum were measured at designated collection times after a single intravesical administration of pirarubicin (30 mg) in 22 patients with superficial bladder cancer. A wide range of concentrations of pirarubicin in bladder cancer tissue was observed (2.3-125 μg/g of tissue), although serum pirarubicin concentrations were not detected in any of the patients. Recurrence of superficial bladder cancer after transurethral resection of the bladder tumor (TUR-BT) was observed in 2 patients (9%). The concentration of pirarubicin in the tumor tissue tended to be higher as the exposure time increased. There was a weak relationship between the pirarubicin tissue concentration and tumor size. However, no significant relationship between tissue pirarubicin concentrations and the prophylactic effect against intravesical recurrence of bladder cancer after TUR-BT was observed. All patients had no adverse events, such as bladder irritation and local toxicity, caused by the treatment with pirarubicin. These findings suggest that prior to single intravesical administration of pirarubicin to patients with superficial bladder cancer the exposure time and tumor size should be considered.
Figures



Similar articles
-
[Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].Hinyokika Kiyo. 1998 Aug;44(8):547-52. Hinyokika Kiyo. 1998. PMID: 9783189 Clinical Trial. Japanese.
-
[A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].Hinyokika Kiyo. 2005 Jul;51(7):439-42. Hinyokika Kiyo. 2005. PMID: 16119805 Clinical Trial. Japanese.
-
[Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].Zhonghua Zhong Liu Za Zhi. 2018 Apr 23;40(4):308-312. doi: 10.3760/cma.j.issn.0253-3766.2018.04.014. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29730921 Chinese.
-
[Postoperative intravesical instillation of THP for superficial bladder tumor: clinical results of prophylactic effects on the recurrence. Fukushima THP Research Group].Gan To Kagaku Ryoho. 1992 Apr;19(4):509-13. Gan To Kagaku Ryoho. 1992. PMID: 1558401 Review. Japanese.
-
Diagnosis and management of superficial bladder cancer.Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. doi: 10.1067/mcn.2001.117539. Curr Probl Cancer. 2001. PMID: 11514784 Review.
Cited by
-
MKP-1 overexpression is associated with chemoresistance in bladder cancer via the MAPK pathway.Oncol Lett. 2020 Aug;20(2):1743-1751. doi: 10.3892/ol.2020.11741. Epub 2020 Jun 16. Oncol Lett. 2020. PMID: 32724417 Free PMC article.
-
Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs: A Pilot Study.Front Pharmacol. 2022 Mar 18;13:837754. doi: 10.3389/fphar.2022.837754. eCollection 2022. Front Pharmacol. 2022. PMID: 35370726 Free PMC article.
-
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.Curr Pharm Des. 2025;31(23):1844-1865. doi: 10.2174/0113816128338217250114073640. Curr Pharm Des. 2025. PMID: 40143399 Review.
-
Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.J Healthc Eng. 2021 Nov 30;2021:2360717. doi: 10.1155/2021/2360717. eCollection 2021. J Healthc Eng. 2021. Retraction in: J Healthc Eng. 2023 Nov 29;2023:9801404. doi: 10.1155/2023/9801404. PMID: 34888022 Free PMC article. Retracted.
References
-
- Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982;127:250–252. - PubMed
-
- Herr HW, Laudone VP, Whitmore WF. An overview of intravesical therapy for superficial bladder tumors. J Urol. 1987;138:1363–1368. - PubMed
-
- Miki T, Nonomura N, Kojima Y, et al. A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer. Hinyokika Kiyo. 1997;43:907–912. (In Japanese). - PubMed
-
- Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970. - PubMed
-
- Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205–1209. - PubMed
LinkOut - more resources
Full Text Sources